Randomised, double-blind, placebo-controlled, multi-centre, parallel group study to investigate the safety and tolerability as well as the immunological and clinical effects of multiple subcutaneous doses of DiaPep277 [Peptide-p277] in latent autoimmune diabetes in adults patients
Phase of Trial: Phase II
Latest Information Update: 07 Sep 2007
At a glance
- Drugs Peptide p277 (Primary)
- Indications Diabetes mellitus
- Focus Therapeutic Use
- 20 Sep 2006 New trial record.